Skip to main content

Table 1 Demographic and clinical details of the 11 patients included in the study

From: Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study

No.

Sex

Age (years)

Height (cm)

Weight (kg)

APACHE II

Serum creatinine (mg/dL)

Bilirubin (mg/dL)

Albumin (g/dL)

Protein (g/dL)

Co-condition

1a

M

69

176

69

21

1.7

2.3

2.1

6.4

 

2a

F

47

160

70

21

1.2

9.2

2.8

5.9

Liver failure

3a

M

81

172

68

15

1.0

2.2

2.1

6.3

 

4b

M

52

180

80

45

1.5

24.0

3.1

5.4

Liver failure

5b

M

78

178

70

25

0.5

3.5

2.6

3.5

Liver failure

6a

M

73

172

86

29

2.4

1.8

3.0

5.7

 

7b

M

56

164

104

31

1.2

11.1

3.0

5.1

Liver cirrhosis

8a

M

37

182

85

21

1.3

43.3

2.8

4.3

Liver transplantation

9a

M

60

180

80

35

0.8

1.8

2.8

4.3

Liver transplantation

10a

M

74

170

73

30

0.7

2.2

2.6

5.6

 

11a

M

75

180

80

30

0.7

0.7

2.7

5.6

ECMO

Median

 

69

176

80

29

1.2

2.3

2.8

5.6

 

Minimum

 

37

160

68

15

0.5

0.7

2.1

3.5

 

Maximum

 

81

182

104

45

2.4

43.3

3.1

6.3

 
  1. APACHE Acute Physiology and Chronic Health Evaluation, ECMO extracorporeal membrane oxygenation, F female, M male
  2. aContinuous veno-venous hemodialysis (CVVHD); b continuous veno-venous hemodiafiltration (CVVHDF)